These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24697678)

  • 1. Efficient and ethical response-adaptive randomization designs for multi-arm clinical trials with Weibull time-to-event outcomes.
    Sverdlov O; Ryeznik Y; Wong WK
    J Biopharm Stat; 2014; 24(4):732-54. PubMed ID: 24697678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group.
    Ryeznik Y; Sverdlov O; Hooker AC
    AAPS J; 2018 Jul; 20(5):85. PubMed ID: 30027336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal response-adaptive randomized designs for multi-armed survival trials.
    Sverdlov O; Tymofyeyev Y; Wong WK
    Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.
    Ryeznik Y; Sverdlov O; Hooker AC
    AAPS J; 2017 Dec; 20(1):24. PubMed ID: 29285730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical considerations for outcome-adaptive trial designs: a clinical researcher's perspective.
    Saxman SB
    Bioethics; 2015 Feb; 29(2):59-65. PubMed ID: 24547903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing statistical and ethical considerations in planning clinical trials: recommendations for response-adaptive randomization urn designs.
    Piccorelli AV; Fraker SA
    J Biopharm Stat; 2018; 28(6):1105-1118. PubMed ID: 29442610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian adaptive randomization designs for targeted agent development.
    Lee JJ; Xuemin Gu ; Suyu Liu
    Clin Trials; 2010 Oct; 7(5):584-96. PubMed ID: 20571130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal and ethical designs for hypothesis testing in multi-arm exponential trials.
    Frieri R; Zagoraiou M
    Stat Med; 2021 May; 40(11):2578-2603. PubMed ID: 33687086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.
    Thall P; Fox P; Wathen J
    Ann Oncol; 2015 Aug; 26(8):1621-8. PubMed ID: 25979922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are outcome-adaptive allocation trials ethical?
    Hey SP; Kimmelman J
    Clin Trials; 2015 Apr; 12(2):102-6. PubMed ID: 25649106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing unequal randomization in clinical trials with heterogeneous treatment costs.
    Sverdlov O; Ryeznik Y
    Stat Med; 2019 Jul; 38(16):2905-2927. PubMed ID: 31049999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal and repeated cross-sectional cluster-randomization designs using mixed effects regression for binary outcomes: bias and coverage of frequentist and Bayesian methods.
    Localio AR; Berlin JA; Have TR
    Stat Med; 2006 Aug; 25(16):2720-36. PubMed ID: 16345043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Block response-adaptive randomization in clinical trials with binary endpoints.
    Magirr D
    Pharm Stat; 2011; 10(4):341-6. PubMed ID: 22328326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.